These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 19858317)

  • 1. Increased apolipoprotein AI production rate and redistribution of high-density lipoprotein size induced by estrogen plus progestin as oral contraceptive.
    Duvillard L; Dautin G; Florentin E; Jeannin A; Pais de Barros JP; Lagrost L; Petit JM; Gambert P; Vergès B
    J Clin Endocrinol Metab; 2009 Dec; 94(12):4891-7. PubMed ID: 19858317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in apolipoprotein B100-containing lipoprotein metabolism due to an estrogen plus progestin oral contraceptive: a stable isotope kinetic study.
    Duvillard L; Dautin G; Florentin E; Petit JM; Gambert P; Vergès B
    J Clin Endocrinol Metab; 2010 May; 95(5):2140-6. PubMed ID: 20200333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
    Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
    Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol.
    Wahl P; Walden C; Knopp R; Hoover J; Wallace R; Heiss G; Rifkind B
    N Engl J Med; 1983 Apr; 308(15):862-7. PubMed ID: 6572785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the effects of triphasic oral contraceptives with desogestrel or levonorgestrel on apolipoprotein A-I-containing high-density lipoprotein particles.
    Cheung MC; Walden CE; Knopp RH
    Metabolism; 1999 May; 48(5):658-64. PubMed ID: 10337871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of desogestrel and gestodene in low-dose oral contraceptive combinations on lipid and lipoprotein status. A randomized prospective study.
    Granata A; Sobbrio GA; D'Arrigo F; Barillari M; Curasì MP; Egitto M; Trimarchi F; Granese D; Pullè C
    Acta Eur Fertil; 1990; 21(3):143-6. PubMed ID: 2149913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic hyperinsulinemia does not increase the production rate of high-density lipoprotein apolipoprotein AI: evidence from a kinetic study in patients with insulinoma.
    Duvillard L; Florentin E; Pont F; Petit JM; Baillot-Rudoni S; Penfornis A; Vergès B
    Arterioscler Thromb Vasc Biol; 2013 Oct; 33(10):2460-5. PubMed ID: 23908245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Desogestrel- and levonorgestrel-containing oral contraceptives have different effects on urinary excretion of prostacyclin metabolites and serum high density lipoproteins.
    Ylikorkala O; Kuusi T; Tikkanen MJ; Viinikka L
    J Clin Endocrinol Metab; 1987 Dec; 65(6):1238-42. PubMed ID: 2960690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral contraceptive and postmenopausal estrogen effects on lipoprotein triglyceride and cholesterol in an adult female population: relationships to estrogen and progestin potency.
    Knopp RH; Walden CE; Wahl PW; Hoover JJ; Warnick GR; Albers JJ; Ogilvie JT; Hazzard WR
    J Clin Endocrinol Metab; 1981 Dec; 53(6):1123-32. PubMed ID: 7298796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
    Teichmann A
    Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():98-104. PubMed ID: 8574257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term effects of prednisone on serum lipids and high density lipoprotein subfractions in normolipidemic healthy men.
    Taskinen MR; Kuusi T; Yki-Järvinen H; Nikkilä EA
    J Clin Endocrinol Metab; 1988 Aug; 67(2):291-9. PubMed ID: 3134387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipoprotein alterations from a triphasic oral contraceptive containing ethinyl estradiol and gestodene. A 12-month trial.
    Moutos DM; Zacur HA; Bachorik PS; Wallach EE
    J Reprod Med; 1994 Sep; 39(9):720-4. PubMed ID: 7807486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism.
    Godsland IF; Crook D; Simpson R; Proudler T; Felton C; Lees B; Anyaoku V; Devenport M; Wynn V
    N Engl J Med; 1990 Nov; 323(20):1375-81. PubMed ID: 2146499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of postmenopausal hormone replacement with oral and transdermal estrogen on high density lipoprotein metabolism.
    Walsh BW; Li H; Sacks FM
    J Lipid Res; 1994 Nov; 35(11):2083-93. PubMed ID: 7868986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical and biochemical effects of two combination oral contraceptive agents.
    Sapire KE; Berger GM; Maritz JS
    S Afr Med J; 1991 Apr; 79(7):376-9. PubMed ID: 1826569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective, one-year study on the effects of two long acting injectable contraceptives (depot-medroxyprogesterone acetate and norethisterone oenanthate) on serum and lipoprotein lipids.
    Enk L; Landgren BM; Lindberg UB; Silfverstolpe G; Crona N
    Horm Metab Res; 1992 Feb; 24(2):85-9. PubMed ID: 1533383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of two monophasic oral contraceptives containing 30 mcg of ethinyl estradiol and either 2 mg of chlormadinone acetate or 0.15 mg of desogestrel on lipid, hormone and metabolic parameters.
    Winkler UH; Sudik R
    Contraception; 2009 Jan; 79(1):15-23. PubMed ID: 19041436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo evidence for the role of lipoprotein lipase activity in the regulation of apolipoprotein AI metabolism: a kinetic study in control subjects and patients with type II diabetes mellitus.
    Frénais R; Nazih H; Ouguerram K; Maugeais C; Zaïr Y; Bard JM; Charbonnel B; Magot T; Krempf M
    J Clin Endocrinol Metab; 2001 May; 86(5):1962-7. PubMed ID: 11344192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No effect of liraglutide on high density lipoprotein apolipoprotein AI kinetics in patients with type 2 diabetes.
    Duvillard L; Pais de Barros JP; Rouland A; Simoneau I; Denimal D; Bouillet B; Petit JM; Vergès B
    Diabetes Metab; 2024 May; 50(3):101535. PubMed ID: 38653365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism.
    Oelkers W; Foidart JM; Dombrovicz N; Welter A; Heithecker R
    J Clin Endocrinol Metab; 1995 Jun; 80(6):1816-21. PubMed ID: 7775629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.